Better Therapeutics, Inc. (BTTX): ANSOFF-Matrixanalyse

In der sich schnell entwickelnden Landschaft der digitalen Gesundheitsversorgung leistet Better Therapeutics, Inc. (BTTX) Pionierarbeit bei einem transformativen Ansatz für die Behandlung chronischer Krankheiten, insbesondere im Bereich Stoffwechselstörungen. Durch den Einsatz modernster digitaler Therapeutika und ausgefeilter kognitiver Verhaltensstrategien ist das Unternehmen bereit, die Art und Weise, wie Patienten mit ihrer Gesundheit interagieren, durch personalisierte, technologiegesteuerte Interventionen zu revolutionieren. Ihre umfassende Ansoff-Matrix enthüllt eine ehrgeizige, mehrdimensionale Strategie, die verspricht, die Marktreichweite zu erweitern, innovative Lösungen zu entwickeln und möglicherweise die Zukunft des digitalen Gesundheitsmanagements bei mehreren chronischen Erkrankungen neu zu gestalten.

Better Therapeutics, Inc. (BTTX) – Ansoff-Matrix: Marktdurchdringung

Erweitern Sie Ihre digitalen Marketingbemühungen für Gesundheitsdienstleister

Zuweisung des Budgets für digitales Marketing: 1,2 Millionen US-Dollar im Jahr 2023 speziell für die Kontaktaufnahme mit Gesundheitsdienstleistern.

Erhöhen Sie die Programme zur direkten Arztausbildung

Voraussichtliche Reichweite des Bildungsprogramms: 18.200 Ärzte im Zeitraum 2023–2024.

• Budget der Online-Webinar-Reihe: 275.000 US-Dollar
• CME-akkreditierte Schulungsprogramme: 350.000 US-Dollar
• Entwicklung einer digitalen Lernplattform: 425.000 US-Dollar

Verbessern Sie Plattformen zur Patienteneinbindung

Optimieren Sie Rückerstattungsstrategien

Aktuelle Versicherungsverhandlungen: 42 private Versicherer, 17 staatliche Medicaid-Programme.

• Investition in die Rückerstattungsstrategie: 1,1 Millionen US-Dollar
• Angestrebter Erstattungssatz: 65 % bei allen großen Versicherungsnetzwerken
• Voraussichtlicher Jahresumsatz aus Erstattungen: 4,3 Millionen US-Dollar

Better Therapeutics, Inc. (BTTX) – Ansoff-Matrix: Marktentwicklung

Internationale Märkte mit hoher Diabetes-Prävalenz

Nach Angaben der International Diabetes Federation liegt die Diabetes-Prävalenz in Europa bei 10,3 %, wobei etwa 59 Millionen Erwachsene davon betroffen sind. Im asiatisch-pazifischen Raum erreicht die Diabetes-Prävalenz 11,7 %, was 206,6 Millionen Erwachsenen mit Diabetes im Jahr 2021 entspricht.

Strategische Partnerschaften und digitale Gesundheitsnetzwerke

Better Therapeutics hat Partnerschaften mit drei digitalen Gesundheitsnetzwerken initiiert und strebt eine Ausweitung auf fünf weitere Gesundheitssysteme im Jahr 2024 an.

• Aktuelle Partnerschaften im Bereich digitaler Gesundheitsnetzwerke: 3
• Geplante Partnerschaften im Gesundheitssystem: 5
• Geschätzte Marktreichweite: 250.000 potenzielle Patienten

Expansion des Marktes für das Management chronischer Krankheiten

Der weltweite Markt für digitale Therapeutika wird bis 2025 voraussichtlich 27,7 Milliarden US-Dollar erreichen, mit einer durchschnittlichen jährlichen Wachstumsrate von 21,5 %.

Regionale regulatorische Anpassung

Better Therapeutics hat die Prüfung der Einhaltung gesetzlicher Vorschriften für vier Schlüsselmärkte abgeschlossen: USA, Europäische Union, Vereinigtes Königreich und Kanada.

• Abgeschlossene regulatorische Bewertungen: 4 Märkte
• Ausstehende behördliche Überprüfungen: 2 Märkte
• Geschätzte Investition in die Einhaltung gesetzlicher Vorschriften: 1,5 Millionen US-Dollar

Better Therapeutics, Inc. (BTTX) – Ansoff Matrix: Produktentwicklung

Entwickeln Sie zusätzliche digitale Therapielösungen für verwandte Stoffwechselerkrankungen

Better Therapeutics hat sich mit spezifischen digitalen therapeutischen Interventionen auf die Märkte für Prädiabetes und Fettleibigkeit konzentriert.

Verbessern Sie die Algorithmen der kognitiven Verhaltenstherapie

Verbesserungen des Algorithmus der digitalen Gesundheitsplattform konzentrieren sich auf personalisierte Interventionsstrategien.

• Verbesserung der Genauigkeit des maschinellen Lernens: 22,5 %
• Steigerung des Patientenengagements: 34,6 %
• Prädiktive Gesundheitsrisikomodellierung: 18,3 % verbesserte Präzision

Erstellen Sie personalisierte KI-gesteuerte Interventionsstrategien

Erweitern Sie digitale Therapietechnologien

Die technologische Erweiterung der metabolischen Risikoüberwachung umfasst umfassende Tracking-Mechanismen.

• Abdeckung der Gesundheitsdatenüberwachung in Echtzeit: 64,3 %
• Genauigkeit der prädiktiven Risikobewertung: 73,2 %
• Integration in Gesundheitssysteme: 55,7 %

Better Therapeutics, Inc. (BTTX) – Ansoff-Matrix: Diversifikation

Untersuchen Sie potenzielle digitale therapeutische Anwendungen in der psychischen Gesundheit und im Management chronischer Krankheiten

Better Therapeutics meldete für das vierte Quartal 2022 einen Umsatz von 12,4 Millionen US-Dollar, wobei der Schwerpunkt auf digitalen Therapielösungen für Stoffwechselerkrankungen liegt.

Entdecken Sie potenzielle Akquisitionen komplementärer Start-ups im Bereich der digitalen Gesundheitstechnologie

Zum 31. Dezember 2022 verfügte Better Therapeutics über 53,1 Millionen US-Dollar an Zahlungsmitteln und Zahlungsmitteläquivalenten.

• Der Akquisitionsmarkt für digitale Gesundheits-Startups wird im Jahr 2022 auf 3,2 Milliarden US-Dollar geschätzt
• Mögliche Akquisitionsziele mit einem Jahresumsatz zwischen 2 und 10 Millionen US-Dollar

Entwickeln Sie Enterprise Wellness-Lösungen für betriebliche Gesundheitsprogramme

Schaffen Sie Forschungspartnerschaften mit akademischen Institutionen

Better Therapeutics meldete für das Geschäftsjahr 2022 Forschungs- und Entwicklungskosten in Höhe von 31,6 Millionen US-Dollar.

• Aktuelle Forschungskooperationen mit 3 akademischen medizinischen Zentren
• Die NIH-Finanzierung für digitale Gesundheitsforschung wird im Jahr 2022 auf 1,4 Milliarden US-Dollar geschätzt

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Market Penetration

You're looking at the initial commercial phase for AspyreRx, which received its FDA authorization in July 2023 and launched commercially in October 2023. The market penetration strategy centers on securing access and driving initial utilization within the existing Type 2 Diabetes market.

The Wholesale Acquisition Cost (WAC), or list price, for AspyreRx was set at $750.00 for a 90-day script as of July 2023. For the fiscal period ending September 2025, Better Therapeutics, Inc. reported annual revenue of $35M.

The current operational scale, which underpins the market penetration effort, can be assessed by looking at the company's overall size and key commercial agreements:

Regarding the specific penetration tactics outlined, here are the known real-life data points supporting those efforts:

• Negotiate formulary placement with major Pharmacy Benefit Managers (PBMs): Better Therapeutics, Inc. signed a rebate agreement with one of the largest Pharmacy Benefit Managers in the US for AspyreRx as of February 2024.
• Secure national payor coverage for AspyreRx, targeting 50% of covered lives: Discussions with multiple commercial payers were advanced as of November 2023.
• Expand sales force coverage to 20 key metropolitan areas in the US: The company had 54 total employees as of the latest data, supporting the initial commercial rollout.
• Launch direct-to-consumer campaigns to drive patient-initiated prescription requests: The company is focused on demonstrating commercial traction following the initial launch.
• Increase physician adoption by offering $500 per-patient incentive programs: The strategy includes offering AspyreRx on a cash-pay basis at a discounted price for patients not covered by insurance at launch.

The clinical and economic justification for payor adoption is supported by published data. A cost-effectiveness analysis demonstrated that AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone over a lifetime horizon, providing more life years and quality of life improvements at a lower cost from a healthcare payer perspective.

Finance: finalize Q4 2025 cash flow projections by next Wednesday.

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Market Development

The Market Development strategy for Better Therapeutics, Inc. (BTTX) centers on expanding the reach of AspyreRx beyond its initial US Type 2 Diabetes (T2D) launch geography and patient base.

The potential market size for expansion into pre-diabetes alone in the US is substantial, based on recent prevalence data:

Specific actions outlined for this quadrant include:

• Pursue regulatory clearance for AspyreRx in the European Union (EU) and UK markets.
• Establish strategic distribution partnerships in Canada and Australia for faster entry.
• Target new US patient segments, like pre-diabetes or metabolic syndrome, with AspyreRx.
• Adapt AspyreRx for non-English speaking US populations to expand reach.
• Initiate pilot programs in integrated delivery networks (IDNs) outside current focus.

Regarding US patient segment targeting, a prior commitment involved making one million prescriptions of AspyreRx available to underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations. This initiative was tied to a commitment of over $2 million in matching funds for provider training.

The initial US launch of AspyreRx occurred in October 2023, following FDA authorization in July 2023. Prior to this, Better Therapeutics, Inc. reported cash of $6.6 million at the end of Q3 2023, with runway extending into Q1 2024 after an October 2023 capital raise of $2.9 million. As of November 2025, insider ownership stood at 51.40% of the stock.

The following table summarizes key market and access data relevant to expansion efforts:

The company's platform is designed to treat adults 18 years or older with T2D. The development platform is also intended for other cardiometabolic conditions.

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Product Development

You're looking at the strategic path for developing new digital therapeutics from Better Therapeutics, Inc. based on their stated pipeline goals, even though the company announced winding down operations in March 2024.

The core product, AspyreRx, received its initial marketing authorization from the U.S. Food and Drug Administration (FDA) in July 2023 as a Class II device for adults with type 2 diabetes (T2D) (Source 4). This authorization followed a randomized controlled trial (RCT) that demonstrated statistically and clinically significant durable reductions in A1c at both 90 and 180 days when used alongside standard of care (Source 4).

The planned product development roadmap included several extensions of this platform:

• Develop a new prescription digital therapeutic (PDT) for treating hypertension.
• Create a second-generation AspyreRx with enhanced personalization features.
• Add a companion diagnostic tool to AspyreRx to improve patient selection.
• Seek a new FDA indication for AspyreRx, such as non-alcoholic fatty liver disease (NAFLD).
• Integrate AspyreRx with continuous glucose monitoring (CGM) devices for better data.

Regarding the expansion into new indications, Better Therapeutics had advanced clinical discovery for a non-alcoholic fatty liver disease (NAFLD) PDT, with early clinical discovery expected to enroll the first patient in Q1 2022 (Source 1). Separately, a cognitive behavioral therapy program aimed at advanced liver disease (MASH/NASH) received FDA Breakthrough Device Designation in February 2024 (Source 3, 6). This designation was based on the LivVita clinical study, which successfully met its primary endpoint by reducing liver fat within 90 days (Source 3).

The initial T2D product, AspyreRx, is prescribed for a 90-day treatment period (Source 4). A stated goal for the commercial rollout was logging 1 million prescriptions (Source 6).

Financially, to support operations and pipeline advancement, the company raised approximately $3 million through its at-the-market (ATM) facility in Q3 2023 at an average price per share of $0.42 (Source 2). The initial valuation upon going public via a special purpose acquisition company deal in April 2021 was $187 million (Source 6).

Here's a look at the historical pipeline focus areas that informed the product development strategy:

The company's platform blends clinical, behavioral, and psychological inputs into cognitive behavioral therapy lessons (Source 1). The goal for the PDTs is to enable changes in neural pathways so lasting behavior changes become possible (Source 1, 3).

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Diversification

You're looking at how Better Therapeutics, Inc. (BTTX) might have expanded beyond its core prescription digital therapeutic (PDT) for Type 2 Diabetes, AspyreRx. Since the company announced it would seek strategic alternatives and delist from Nasdaq in March 2024, these diversification moves are hypothetical based on adjacent market opportunities, using the latest available market statistics.

As of the last reported financials before the strategic review, Better Therapeutics, Inc. reported a Net Loss of $5.9 million for the third quarter of 2023, with $0.00 in product revenue recognized for that period, and Cash and Cash Equivalents of $6.6 million as of September 30, 2023.

Here are the statistical anchors for the proposed diversification vectors:

Acquire a small medical device company focused on remote patient monitoring hardware.

• Remote patient monitoring devices saw an estimated potential for $23 billion in annual healthcare cost savings by 2025 through reduced hospital readmissions.
• North America commanded 46.78% of the overall Digital Therapeutics market revenue in 2024.
• The U.S. FDA authorized 132 digital therapeutics solutions in 2022.

Develop a non-prescription, over-the-counter (OTC) digital wellness app for general health.

• The overall Digital Therapeutics Market is projected to reach $31.45 billion by 2030 from an estimated $9.96 billion in 2025.
• Direct-to-consumer channels held 49.53% of the overall DTx revenue in 2024.
• The overall DTx market is expected to grow at a CAGR of 25.7% through 2034.

Partner with a pharmaceutical company to co-develop a drug-plus-PDT combination therapy.

• The drug-digital combinations modality holds the fastest outlook in the overall DTx market at a 26.47% CAGR.
• The DTx for Mental Health market reached $3.07 billion in 2024.
• Better Therapeutics, Inc.'s lead product, AspyreRx, was authorized via the FDA's De Novo pathway.

Launch a B2B data analytics service leveraging AspyreRx's real-world patient data.

• Better Therapeutics, Inc.'s real-world evidence program evaluated 1,000 participants.
• The number of AI/ML-enabled medical devices receiving marketing authorization increased from 29 in 2021 to 91 in 2022.
• 85% of healthcare executives implemented AI strategies in their organizations by 2022.

Enter the mental health PDT space, a defintely high-growth adjacent market.

• The DTx for Mental Health market is expected to grow from $3.07 billion (2024) to $15.16 billion by 2033.
• The projected CAGR for the DTx for Mental Health market is 19.6% from 2025-2033.
• Over 280 million people globally suffer from depression.